Insys Therapeutics Inc (NASDAQ:INSY) Institutional Investor Sentiment Analysis

April 17, 2018 - By Clifton Ray

Sentiment for Insys Therapeutics Inc (NASDAQ:INSY)

Insys Therapeutics Inc (NASDAQ:INSY) institutional sentiment decreased to 0.76 in 2017 Q4. Its down -0.49, from 1.25 in 2017Q3. The ratio worsened, as 38 hedge funds opened new and increased equity positions, while 50 sold and trimmed holdings in Insys Therapeutics Inc. The hedge funds in our partner’s database now have: 16.43 million shares, down from 18.21 million shares in 2017Q3. Also, the number of hedge funds holding Insys Therapeutics Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 21 Reduced: 29 Increased: 18 New Position: 20.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $499.75 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

The stock increased 8.05% or $0.51 during the last trading session, reaching $6.78. About 822,309 shares traded or 7.21% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 45.03% since April 17, 2017 and is downtrending. It has underperformed by 56.58% the S&P500.

Orbimed Advisors Llc holds 0.66% of its portfolio in INSYS Therapeutics, Inc. for 5.41 million shares. Mirae Asset Global Investments Co. Ltd. owns 1.47 million shares or 0.19% of their US portfolio. Moreover, Gsa Capital Partners Llp has 0.04% invested in the company for 67,200 shares. The California-based Eqis Capital Management Inc. has invested 0.03% in the stock. Tci Wealth Advisors Inc., a Arizona-based fund reported 7,766 shares.#img1#

INSYS Therapeutics, Inc. (NASDAQ:INSY) Ratings Coverage

Ratings analysis reveals 67% of Insys Therapeutics’s analysts are positive. Out of 3 Wall Street analysts rating Insys Therapeutics, 2 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8.0 while the high is $14.0. The stock’s average target of $9.50 is 40.12% above today’s ($6.78) share price. INSY was included in 4 notes of analysts from October 18, 2017. The rating was downgraded by PiperJaffray on Friday, March 9 to “Underweight”. Jefferies maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) on Friday, November 3 with “Buy” rating. On Wednesday, October 18 the stock rating was maintained by Jefferies with “Buy”. The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) has “Buy” rating given on Friday, October 27 by RBC Capital Markets.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.